Allianz Asset Management GmbH - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 171 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2019. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.

Quarter-by-quarter ownership
Allianz Asset Management GmbH ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$303,025
-22.7%
8,5000.0%0.00%0.0%
Q2 2023$392,105
-74.2%
8,500
-66.7%
0.00%0.0%
Q2 2022$1,522,000
-41.6%
25,495
-28.9%
0.00%
-50.0%
Q1 2022$2,604,000
-6.7%
35,860
+8.1%
0.00%0.0%
Q4 2021$2,792,000
-28.6%
33,188
-23.5%
0.00%
-33.3%
Q3 2021$3,911,000
+121.0%
43,361
+133.6%
0.00%
+50.0%
Q2 2021$1,770,000
-14.3%
18,562
+2.3%
0.00%0.0%
Q1 2021$2,066,000
-19.8%
18,144
-2.5%
0.00%
-33.3%
Q4 2020$2,576,000
+126.2%
18,606
+34.2%
0.00%
+200.0%
Q3 2020$1,139,000
+12.7%
13,866
+7.3%
0.00%0.0%
Q2 2020$1,011,000
-53.5%
12,928
-58.8%
0.00%
-50.0%
Q1 2019$2,175,000
+164.3%
31,364
+65.7%
0.00%
+100.0%
Q4 2018$823,000
+132.5%
18,933
+232.1%
0.00%
Q2 2017$354,000
-20.4%
5,701
-13.1%
0.00%
Q1 2017$445,000
-26.1%
6,558
-23.4%
0.00%
-100.0%
Q4 2016$602,000
-56.7%
8,559
-56.3%
0.00%0.0%
Q3 2016$1,390,000
-78.9%
19,588
-81.2%
0.00%
-87.5%
Q1 2016$6,580,000
-60.6%
103,933
-29.9%
0.01%
-57.9%
Q4 2015$16,681,000
-2.6%
148,190
-16.7%
0.02%
-5.0%
Q3 2015$17,135,000
+38.7%
177,914
+47.5%
0.02%
+53.8%
Q2 2015$12,351,000
+485.1%
120,625
+254.8%
0.01%
+550.0%
Q1 2015$2,111,00034,0000.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q2 2019
NameSharesValueWeighting ↓
First Light Asset Management, LLC 437,512$31,772,0002.80%
RTW INVESTMENTS, LP 1,373,284$99,728,0002.06%
Rock Springs Capital Management LP 1,028,109$74,661,0001.88%
Privium Fund Management B.V. 112,727$8,186,0001.81%
Avidity Partners Management LP 869,000$63,107,0001.31%
SUVRETTA CAPITAL MANAGEMENT, LLC 525,100$38,133,0001.16%
Boxer Capital, LLC 200,000$14,524,0000.75%
SECTOR GAMMA AS 46,221$3,357,0000.73%
FEDERATED HERMES, INC. 3,987,728$289,589,0000.65%
EMERALD ADVISERS, LLC 223,952$16,263,0000.62%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders